Publications




Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.
J Clin Oncol 2017 Mar 13;35(9):984-993. Epub 2017 Feb 13.
All authors: Dana-Farber Cancer Institute; Romain Guièze and Catherine J. Wu, Harvard Medical School; Catherine J. Wu, Brigham and Women's Hospital, Boston; Romain Guièze and Catherine J. Wu, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Gregory Lazarian, U978 Institut National de la Santé et de la Recherche Médicale and Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny; and Romain Guièze, Centre Hospitalier Universitaire de Clermont-Ferrand and Université d'Auvergne, Clermont-Ferrand, France.

Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.
Cancer Cell 2016 Nov 3;30(5):750-763. Epub 2016 Nov 3.
Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney Street, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address:

Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.
Cancer Cell 2016 Sep;30(3):404-417
Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
N Engl J Med 2016 Jul;375(2):143-53
From the Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School (M.S.D., H.T.K., P.B., R.L., A.S., A.P.L., M.H., M.S., F.S.H., C.J.W., V.T.H., C. Cutler, J.K., E.P.A., J.H.A., P.A., J.R., R.J.S.), the Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center and Harvard Medical School (D.A.), the Bone Marrow Transplant Program, Massachusetts General Hospital Cancer Center and Harvard Medical School (Y.-B.C.), the Departments of Dermatology (N.R.L.) and Pathology (S.R.G., J.L.H., S.J.R.), Dana-Farber and Brigham and Women's Cancer Center, and the Dana-Farber Cancer Institute, Center for Molecular Oncologic Pathology (M.B., C.W.Z.) - all in Boston; Broad Institute of Massachusetts Institute of Technology and Harvard (P.B., C.J.W.) and Neon Therapeutics (M.S.R.) - both in Cambridge; the Blood and Marrow Transplant Program, University of California, San Diego, Moores Cancer Center, La Jolla (C. Costello, E.D.B.); Colorado Blood Cancer Institute, Denver (P.M.); Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (H.S.); and the Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta (A.B.).


Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma.
Cell Rep 2016 Apr 14. Epub 2016 Apr 14.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:






The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.
Nat Med 2015 Jun 25;21(6):572-80. Epub 2015 May 25.
1] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Pathology, Brigham &Women's Hospital, Boston, Massachusetts, USA.

Haematological malignancies: at the forefront of immunotherapeutic innovation.
Nat Rev Cancer 2015 Apr 19;15(4):201-15. Epub 2015 Mar 19.
1] Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Broad Institute, Cambridge, Massachusetts 02142, USA. [3] Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Cell 2015 Jan;160(1-2):48-61
The Broad Institute, Cambridge, MA 02142, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Center for Immunology and Inflammatory Diseases and Department of Medicine, Massachusetts General Hospital, Charlestown, MA 02129, USA. Electronic address:

Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia.
Cancer Cell 2014 Dec;26(6):813-825
Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Division of Hematology/Oncology, Children's Hospital, Boston, MA 02115, USA. Electronic address:

Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.
Blood 2014 Aug 28;124(7):1089-98. Epub 2014 Apr 28.
Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.
Blood 2014 Jul 2;124(3):453-62. Epub 2014 Jun 2.
Cancer Vaccine Center and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;

Vaccines and melanoma.
Hematol Oncol Clin North Am 2014 Jun 3;28(3):559-69. Epub 2014 Apr 3.
Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02215, USA; Cancer Vaccine Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

HLA-binding properties of tumor neoepitopes in humans.
Cancer Immunol Res 2014 Jun 3;2(6):522-9. Epub 2014 Mar 3.
Authors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, Massachusetts


Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.
Biol Blood Marrow Transplant 2013 Nov 6;19(11):1537-45. Epub 2013 Sep 6.
Experimental Transplantation Immunology Branch, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland.










Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.
Clin Cancer Res 2010 May 11;16(10):2729-39. Epub 2010 May 11.
Cancer Vaccine Center and Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Skin Disease Research Center, Harvard Medical School, Boston, Massachusetts 02115, USA.

Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.
Clin Cancer Res 2010 Mar 16;16(5):1642-51. Epub 2010 Feb 16.
Division of Hematologic Malignancies, Cancer Vaccine Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.
Cancer Res 2010 Feb 26;70(3):906-15. Epub 2010 Jan 26.
Cancer Vaccine Center and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.
Cancer Res 2010 Feb 2;70(4):1344-55. Epub 2010 Feb 2.
Cancer Vaccine Center and Departments of Medical Oncology and Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.




Inflammatory myopathy associated with imatinib mesylate therapy.
J Clin Neuromuscul Dis 2004 Mar;5(3):119-21
From the Department of *Neurology, Lahey Clinic, Burlington, Massachusetts, and Tufts University School of Medicine, Boston, Massachusetts; the Department of daggerHematology/Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; and the Department of double daggerNeurology, Brigham and Women's Hospital, Harvard Medical School Boston, Massachusetts.

Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.
Blood 2002 Jun;99(12):4610-7
Center for Hematologic Oncology and Department of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.




Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
Immunity 2017 02;46(2):197-204
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction.
Immunity 2017 02;46(2):315-326
Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA; Harvard Medical School, Boston, MA, 02115, USA. Electronic address:


OF